MedPath

Flutamide

Generic Name
Flutamide
Brand Names
Eulexin
Drug Type
Small Molecule
Chemical Formula
C11H11F3N2O3
CAS Number
13311-84-7
Unique Ingredient Identifier
76W6J0943E
Background

An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Indication

For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate

Associated Conditions
Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate

Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3
Conditions
Prostate Cancer
First Posted Date
2003-12-09
Last Posted Date
2016-07-21
Lead Sponsor
St. Luke's Hospital, Ireland
Target Recruit Count
276
Registration Number
NCT00003734
Locations
🇮🇪

Cork University Hospital, Cork, Ireland

🇮🇪

Letterkenny Hospital, Donnegal, Ireland

🇮🇪

St. Vincent's Hospital, Dublin, Ireland

and more 9 locations

Hormone Therapy in Treating Patients With Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Sexual Dysfunction and Infertility
Interventions
Other: quality-of-life assessment
First Posted Date
2003-08-13
Last Posted Date
2016-07-04
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
101
Registration Number
NCT00003323
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

🇺🇸

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States

and more 40 locations

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

Phase 3
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2003-07-15
Last Posted Date
2020-04-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
64
Registration Number
NCT00003645
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
First Posted Date
2003-04-18
Last Posted Date
2014-01-06
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Target Recruit Count
105
Registration Number
NCT00003124
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
First Posted Date
2003-02-06
Last Posted Date
2023-08-04
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
25
Registration Number
NCT00054106
Locations
🇨🇦

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: LHRH agonist
Radiation: radiation therapy
First Posted Date
2003-01-27
Last Posted Date
2022-06-15
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
1579
Registration Number
NCT00005044
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 258 locations

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

First Posted Date
2003-01-27
Last Posted Date
2020-10-22
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
21
Registration Number
NCT00030654
Locations
🇺🇸

Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

🇺🇸

Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States

🇺🇸

Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States

and more 75 locations

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2020-04-03
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
361
Registration Number
NCT00002633
Locations
🇨🇦

QEII Health Sciences Center, Halifax, Nova Scotia, Canada

🇨🇦

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇨🇦

Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada

and more 12 locations

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

First Posted Date
2003-01-27
Last Posted Date
2021-06-23
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
1386
Registration Number
NCT00003653
Locations
🇨🇦

BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

🇨🇦

BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada

🇨🇦

Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada

and more 26 locations

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

First Posted Date
2003-01-27
Last Posted Date
2018-10-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
306
Registration Number
NCT00002855
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath